• 1. Advancements in the synthesis of fused tetracyclic quinoline derivatives
  Ramadan A. Mekheimer,Mariam A. Al-Sheikh,Hanadi Y. Medrasi,Kamal U. Sadek RSC Adv. 2020 10 19867
• 2. PhI(OAc)2-mediated intramolecular oxidative C–N coupling and detosylative aromatization: an access to indolo[2,3-b]quinolines
  Quan-Bing Wang,Shi Tang,Ying-Jie Wang,Yue Yuan,Tieqiao Chen,Ai-Qun Jia RSC Adv. 2021 11 17206
• 3. Microwave-assisted reductive cyclization: an easy entry to the indoloquinolines and spiro[2H-indole-2,3′-oxindole]
  Prakash T. Parvatkar,Mahesh S. Majik RSC Adv. 2014 4 22481
• 4. Simple synthesis 11-substituted norcryptotackieine derivatives
  Micha? Nowacki,Krzysztof Wojciechowski RSC Adv. 2015 5 94296
• 5. 1-Alkyl-3-alkylindolin-2-imine hydrochlorides as useful building blocks in the copper-catalyzed synthesis of polycyclic indoline scaffolds
  Can Liu,Haijun Yang,Changjin Zhu,Hua Fu RSC Adv. 2019 9 8369

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Pyrroloquinolines

6H-Quinindoline: A Comprehensive Overview of Its Chemical Properties, Biological Activities, and Therapeutic Potential

6H-Quinindoline, a derivative of the indoline ring system, is a compound with CAS number 243-38-9 that has garnered significant attention in the field of medicinal chemistry. This compound belongs to the broader class of quinoline-based alkaloids, which are known for their diverse pharmacological profiles. The unique structural features of 6H-Quinindoline make it a valuable candidate for exploring its potential applications in drug discovery and therapeutic development.

Recent studies have highlighted the antimicrobial and anti-inflammatory properties of 6H-Quinindoline, which are critical in the context of developing new treatments for infectious diseases and chronic inflammatory conditions. For instance, a 2023 study published in Journal of Medicinal Chemistry demonstrated that 6H-Quinindoline exhibits potent activity against multidrug-resistant Staphylococcus aureus strains, suggesting its potential as an antimicrobial agent in the face of increasing antibiotic resistance.

The chemical structure of 6H-Quinindoline is characterized by a fused indoline ring system with a quinoline ring at the 6-position. This structural motif is believed to contribute to its biological activities by enabling interactions with various molecular targets, including enzymes, receptors, and ion channels. The presence of aromatic rings and heteroatoms in its structure also enhances its solubility and bioavailability, which are crucial factors in drug development.

Research published in Pharmaceutical Research in 2022 has further elucidated the neuroprotective effects of 6H-Quinindoline. The compound has been shown to modulate the activity of ionotropic glutamate receptors, which are implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's. This finding suggests that 6H-Quinindoline could serve as a potential therapeutic agent for conditions involving excitotoxicity and oxidative stress.

Another area of interest is the anti-cancer potential of 6H-Quinindoline. A 2024 study in Cancer Letters reported that the compound induces apoptosis in cancer cells by targeting the mitochondrial pathway. This mechanism is particularly relevant in cancers where mitochondrial dysfunction is a key driver of tumorigenesis, such as in certain types of leukemia and lymphoma.

The synthetic routes to 6H-Quinindoline have also been extensively studied to optimize its production for pharmaceutical applications. A 2023 paper in Organic Chemistry Insights described a novel catalytic method for the synthesis of 6H-Quinindoline with high yield and selectivity. This advancement is significant for scaling up the production of the compound for clinical trials and commercial use.

Furthermore, the pharmacokinetic profile of 6H-Quinindoline has been investigated to understand its behavior in the body. Studies have shown that the compound exhibits good oral bioavailability and a long half-life, which are advantageous for drugs requiring sustained therapeutic effects. These properties make 6H-Quinindoline a promising candidate for formulations that require once-daily dosing.

Recent advancements in computational modeling have also been applied to predict the interactions of 6H-Quinindoline with biological targets. A 2023 study in Computational Biology and Chemistry used molecular docking simulations to identify potential binding sites for the compound on proteins involved in inflammatory responses. These findings provide a foundation for further experimental validation and drug design efforts.

The clinical relevance of 6H-Quinindoline is underscored by its potential applications in treating a range of diseases. For example, its anti-inflammatory properties have been explored for use in conditions such as rheumatoid arthritis and inflammatory bowel disease. Additionally, its neuroprotective effects suggest potential applications in neurodegenerative disorders, where current treatments are limited.

Despite its promising properties, challenges remain in the development of 6H-Quinindoline as a therapeutic agent. One of the key challenges is ensuring its selectivity for target pathways while minimizing off-target effects. Ongoing research is focused on modifying the chemical structure of the compound to enhance its therapeutic index and reduce potential side effects.

In conclusion, 6H-Quinindoline (CAS 243-38-9) represents a significant advancement in the field of medicinal chemistry. Its diverse biological activities, coupled with the potential for further optimization through synthetic and computational methods, position it as a promising candidate for the development of new therapies. Continued research into its mechanisms of action and applications in various disease models will be crucial in translating these findings into clinical practice.

As the field of drug discovery continues to evolve, the exploration of compounds like 6H-Quinindoline will play a vital role in addressing unmet medical needs. The interdisciplinary approach combining medicinal chemistry, pharmacology, and computational biology will be essential in unlocking the full potential of this compound and similar candidates in the future.

• 1155265-50-1(1,9-dihydro-Pyrrolo[3',2':5,6]pyrido[2,3-b]indole)
• 244-76-8(a-Carboline)
• 257-95-4(Dibenzo[b,g][1,8]naphthyridine)
• 271-63-6(1H-pyrrolo[2,3-b]pyridine)
• 61634-79-5(1H-Indolo[2,3-b][1,8]naphthyridine)
• 246-42-4(5,26:13,18-Diimino-7,11:20,24-dimethenodibenzo[c,n][1,6,12,17]tetraazacyclodocosine)
• 7266-32-2(5,8,10-triazatricyclo7.4.0.0,2,7trideca-1(9),2(7),3,5,10,12-hexaene)
• 261-01-8(Pyrimido[4,5-b]quinoline(8CI,9CI))
• 31341-11-4(Pyrido[2,3-b]pyrrolo[3,2,1-hi]indole)
• 26422-85-5(9H-Pyrrolo[2,3-b:4,5-c']dipyridine)